{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:11:21Z","timestamp":1778098281585,"version":"3.51.4"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172561"],"award-info":[{"award-number":["81172561"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0237098","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T17:24:06Z","timestamp":1596475446000},"page":"e0237098","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3"],"prefix":"10.1371","volume":"15","author":[{"given":"Maoxiao","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqiong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-5279","authenticated-orcid":true,"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"pone.0237098.ref001","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"CR Chong","year":"2013","journal-title":"Nat Med"},{"key":"pone.0237098.ref002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"S Sigismund","year":"2018","journal-title":"Mol Oncol"},{"key":"pone.0237098.ref003","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"LV Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"pone.0237098.ref004","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"TS Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0237098.ref005","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"AY Helena","year":"2013","journal-title":"Clin Cancer Res"},{"key":"pone.0237098.ref006","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial","volume":"34","author":"SM Magrini","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0237098.ref007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"E Van Cutsem","year":"2015","journal-title":"J Clin Oncol"},{"key":"pone.0237098.ref008","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4161\/cbt.11.9.15050","article-title":"Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab","volume":"11","author":"TM Brand","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"pone.0237098.ref009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nm.2646","article-title":"The road to resistance: EGFR mutation and cetuximab","volume":"18","author":"A Bardelli","year":"2012","journal-title":"Nat Med"},{"key":"pone.0237098.ref010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s12253-016-0160-8","article-title":"Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line","volume":"23","author":"J Chen","year":"2017","journal-title":"Pathology & Oncology Research"},{"key":"pone.0237098.ref011","first-page":"1968","article-title":"The construction and characterization of a novel adenovirus vector of artificial microRNA targeting EGFR","volume":"12","author":"P Chen","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"pone.0237098.ref012","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/cr.2010.9","article-title":"Nuclear entry of active caspase-3 is facilitated by its p3-recognition-based specific cleavage activity","volume":"20","author":"M Luo","year":"2010","journal-title":"Cell Res"},{"key":"pone.0237098.ref013","doi-asserted-by":"crossref","first-page":"10107","DOI":"10.1074\/jbc.273.17.10107","article-title":"Generation of constitutively active recombinant caspases-3 and-6 by rearrangement of their subunits","volume":"273","author":"SM Srinivasula","year":"1998","journal-title":"J Biol Chem"},{"key":"pone.0237098.ref014","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/cgt.2012.5","article-title":"Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma","volume":"19","author":"J Chen","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"pone.0237098.ref015","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ygyno.2011.04.052","article-title":"Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells","volume":"122","author":"E Hoskins","year":"2011","journal-title":"Gynecol Oncol"},{"key":"pone.0237098.ref016","doi-asserted-by":"crossref","first-page":"108292","DOI":"10.18632\/oncotarget.22660","article-title":"Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers","volume":"8","author":"SV Kozin","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0237098.ref017","doi-asserted-by":"crossref","first-page":"e144088","DOI":"10.1016\/j.gene.2019.144088","article-title":"The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis","volume":"720","author":"W Xie","year":"2019","journal-title":"Gene"},{"key":"pone.0237098.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2016.02.004","article-title":"Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort","volume":"55","author":"CMP Campbell","year":"2016","journal-title":"Oral Oncol"},{"key":"pone.0237098.ref019","first-page":"6503","article-title":"Targeted gene therapy of the HSV-TK\/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro","volume":"15","author":"S Hao","year":"2018","journal-title":"Oncol Lett"},{"key":"pone.0237098.ref020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/bios5020199","article-title":"Application of xCELLigence RTCA biosensor technology for revealing the profile and window of drug responsiveness in real time","volume":"5","author":"D Kho","year":"2015","journal-title":"Biosensors"},{"key":"pone.0237098.ref021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"P Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"pone.0237098.ref022","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2013.06.010","article-title":"Nuclear EGFR as a molecular target in cancer","volume":"108","author":"TM Brand","year":"2013","journal-title":"Radiother Oncol"},{"key":"pone.0237098.ref023","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4161\/cbt.20846","article-title":"Preclinical modeling of EGFR inhibitor resistance in head and neck cancer","volume":"13","author":"KM Quesnelle","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"pone.0237098.ref024","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1349-7006.2007.00510.x","article-title":"Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor","volume":"98","author":"H Kimura","year":"2007","journal-title":"Cancer Sci"},{"key":"pone.0237098.ref025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nmeth923","article-title":"Lessons from Nature: microRNA-based shRNA libraries","volume":"3","author":"K Chang","year":"2006","journal-title":"Nature methods"},{"key":"pone.0237098.ref026","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"L Galluzzi","year":"2012","journal-title":"Oncogene"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T17:24:23Z","timestamp":1596475463000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0237098"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0237098","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]}}}